- 2.14% of patients with anaplastic lymphoma kinase (ALK)-positive advanced NSCLC developed ALK inhibitor-related pneumonitis, according to a meta-analysis that also found patients in Japan had a higher incidence of ALK pneumonitis compared with patients from other countries.
- Patients treated with brigatinib had the highest incidence of pneumonitis compared with those treated with other ALK inhibitors.
Why this matters
- NSCLC with ALK rearrangement is rare, accounting for only about 5% of all NSCLC cases, so data on ALK pneumonitis were lacking.
- Meta-analysis of 18 studies involving 2261 patients treated with ALK inhibitor monotherapy for advanced NSCLC.
- Funding: None disclosed.
- Overall pooled incidence of pneumonitis was 2.14% for all-grade, 1.33% for high-grade, 0.22% for grade-5.
- Patients treated with brigatinib had the highest incidence of all-grade pneumonitis at 4.11% (aOR, 4.827; P=.007).
- Pneumonitis incidence was significantly higher in studies from Japan than in those from other countries for all-grade (6.25% vs 1.14%; P<.001 and high-grade pneumonitis vs p>
- After multivariable analysis, cohorts from Japanese studies had significantly higher risk of all-grade pneumonitis than cohorts from other countries (OR, 4.329; P<.001>
- Only 20 cohorts included in meta-analysis.
- No patient-level data.